LACTOLOGY FOUNDATION

Toxicological and Lactological Monograph on ATC Class A07F: Antidiarrheal Microorganisms

ATC Class and General Pharmacology

The Anatomical Therapeutic Chemical (ATC) classification system established by the World Health Organization (WHO) categorizes antidiarrheal microorganisms under the alphanumeric code A07F. This therapeutic subgroup belongs to the broader category A07 (Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents) within anatomical main group A, which designates agents targeting the alimentary tract and metabolism. Pharmacologically, class A07F comprises viable non-pathogenic bacteria and unicellular fungi formulated as live biotherapeutic products intended to restore gastrointestinal microecology, reinforce mucosal barrier integrity, and antagonize pathogenic enteropathogens during diarrheal disease states.

Within the hierarchy of class A07F, the fourth-level level subgroup A07FA encompasses all standardized therapeutic preparations of antidiarrheal microorganisms. These live biotherapeutic products are subdivided into distinct chemical and biological Fifth-Level subclasses based on strain taxonomy and combination status.

The pharmacodynamics of subclass A07FA01 (Lactic acid producing organisms) center on the enzymatic fermentation of luminal carbohydrates into short-chain fatty acids (SCFAs)—primarily acetate, propionate, and butyrate—and lactic acid. This metabolic activity lowers the intraluminal pH of the colon, creating an acidic microenvironment that directly suppresses the proliferation of acid-sensitive pathogenic species such as Salmonella enterica, Shigella flexneri, and enterotoxigenic Escherichia coli. Concurrently, generated butyrate acts as the primary energetic substrate for colonocytes, upregulating the transcription of tight junction proteins including zonula occludens-1 (ZO-1) and occludin, thereby reducing epithelial permeability and inhibiting macromolecular pathogen translocation.

Subclass A07FA02 (Saccharomyces boulardii) operates through mechanisms distinct from bacterial biotherapeutics. As a non-pathogenic yeast, S. boulardii is naturally resistant to antibacterial agents, preserving its pharmacodynamic efficacy during concurrent systemic antibiotic administration. S. boulardii secretes a 54-kDa zinc metalloprotease that directly digests Clostridioides difficile Toxins A and B, neutralizing their cytotoxic and enterotoxic activity on the colonic brush border. Additionally, S. boulardii produces a 120-kDa protein that inhibits Vibrio cholerae toxin-induced intracellular cyclic adenosine monophosphate (cAMP) accumulation, directly attenuating secretory diarrhea. The yeast also releases polyamines, such as spermine and spermidine, which stimulate enterocyte brush-border membrane expression of digestive enzymes including sucrase, lactase, and maltase, accelerating mucosal recovery.

Subclass A07FA03 (Escherichia coli, specifically the probiotic strain Nissle 1917) exerts antidiarrheal actions through competitive exclusion and direct antagonism. Lacking pathogenic virulence factors such as alpha-hemolysins, enterotoxins, or focal adhesion determinants, E. coli Nissle 1917 synthesizes antimicrobial peptides termed microcins (specifically microcins M and H47) that selectively inhibit closely related Gram-negative enteropathogens. Furthermore, this strain exhibits high-affinity siderophore systems (including enterobactin, salmochelin, and aerobactin) that sequester free ferric iron within the gut lumen, outcompeting pathogenic invaders for this essential trace element.

Subclass A07FA51 (Lactic acid producing organisms, combinations) leverages ecological complementary interactions between distinct bacterial strains. Multi-strain formulations pairing Lactobacillus species, which preferentially colonize the upper small intestine, with Bifidobacterium species, which dominate the distal ileum and cecum, provide multi-locus antimicrobial coverage along the entire length of the gastrointestinal tract.

Toxicological Profile

The toxicology of ATC class A07F live biotherapeutic agents differs fundamentally from standard small-molecule xenobiotics. Because these microorganisms function exclusively within the lumen and mucosal mucosa of the gastrointestinal tract, systemic absorption is virtually non-existent under physiological conditions, resulting in an absolute oral bioavailability ($F$) approaching 0%. Consequently, traditional xenobiotic toxicological phenomena—such as systemic organ toxicity, cytochrome P450 hepatic metabolism, and renal tubular clearance—do not occur with A07F formulations.

Preclinical safety evaluations of A07F strains reveal an absence of acute, subchronic, or chronic toxicity. Standard toxicological assessments, including oral high-dose acute toxicity testing, genotoxicity assays, mutagenicity testing, and carcinogenicity models, consistently demonstrate no target-organ damage or genomic instability. Live biotherapeutic strains classified under A07F are characterized by a complete absence of transferable antibiotic-resistance plasmids encoding resistance to critical human antimicrobials, preventing horizontal gene transfer to opportunistic pathogens within the native gut microbiota.

In healthy host organisms, clinical adverse reactions associated with A07F agents are localized to the alimentary canal, remaining transient and low in severity. The rapid fermentation of luminal carbohydrates following initial dosing can induce transient meteorism, flatulence, abdominal distension, and minor alterations in stool frequency. These symptoms typically resolve spontaneously within several days as microecological equilibrium is re-established.

The primary toxicological concern associated with live biotherapeutic microorganisms involves opportunistic systemic translocation resulting in bacteremia, endocarditis, or fungemia. In individuals with intact intestinal mucosa and functional innate and adaptive immune systems, mucosal tight junctions and luminal secretory IgA prevent the passage of viable microorganisms into the portal venous or lymphatic circulations. However, when structural mucosal integrity is breached or systemic immunity is severely impaired, translocation can occur.

For subclass A07FA01 (Lactic acid producing organisms), systemic translocation resulting in Lactobacillus or Bifidobacterium bacteremia is rare, with epidemiological surveillance establishing an incidence rate below 1 case per 1,000,000 clinical users. Identified clinical predisposing factors include severe absolute neutropenia, major gastrointestinal mucosal disruption (such as severe ulceration from ulcerative colitis or post-chemotherapy mucositis), and short bowel syndrome.

For subclass A07FA02 (Saccharomyces boulardii), systemic translocation manifests as S. boulardii fungemia. The estimated risk of S. boulardii fungemia is approximately 1 case per 5,600,000 users, occurring almost exclusively in critically ill patients treated in intensive care units. Clinical investigations demonstrate that S. boulardii fungemia primarily arises not through direct enteral translocation across damaged enterocytes, but via nosocomial vascular catheter contamination. Opening packets or crushing capsules of S. boulardii creates aerosolized yeast particles that can settle on central venous catheter (CVC) hubs, leading to direct intravascular colonization and subsequent bloodstream infection.

For subclass A07FA03 (Escherichia coli Nissle 1917), systemic toxicity or bacteremia in immunocompetent hosts is non-existent due to the deletion or inactivation of virulence factors required for cellular invasion, serum resistance, and systemic dissemination.

Lactation Pharmacology and Infant Exposure

Determining the excretion of a pharmacological substance into human breast milk requires evaluating key physicochemical parameters, including systemic maternal plasma concentrations, molecular weight, lipophilicity, protein binding, and the milk-to-plasma ($M/P$) ratio. Live microorganisms classified under ATC class A07F do not meet the criteria for passive passage across the blood-milk barrier.

Following oral ingestion, viable cells of Lactobacillus, Bifidobacterium, E. coli, and S. boulardii remain confined to the maternal gastrointestinal lumen. They do not undergo enteral vascular absorption and do not circulate within the maternal blood compartment. Because maternal systemic plasma concentrations of orally administered A07F microorganisms are zero, passive transfer across the vascular endothelial and alveolar epithelial barriers of the lactating mammary gland cannot occur. Consequently, xenobiotic drug excretion of live biotherapeutic agents into milk is functionally absent, yielding an Absolute Infant Dose (AID) of 0 mg/kg/day and a Relative Infant Dose (RID) of 0%.

Although direct passive drug transfer into breast milk does not occur, maternal ingestion of A07F microorganisms influences breast milk composition and infant exposure through an biological mechanism known as the enteromammary pathway. This endogenous physiological route allows maternal gut-derived signals and commensal microorganisms to interact with the lactating mammary gland without inducing systemic bacteremia.

The enteromammary pathway is initiated within the maternal gut-associated lymphoid tissue (GALT), specifically within Peyer's patches and mesenteric lymph nodes. Specialized CD18+ dendritic cells and intestinal mononuclear phagocytes sample viable non-pathogenic bacteria directly from the maternal intestinal lumen. Rather than destroying these commensal strains, dendritic cells retain small numbers of intact organisms and migrate through the mesenteric lymphatic system into the thoracic duct.

Simultaneously, lactogenic hormones, predominantly prolactin and oxytocin, upregulate specific adhesion molecules and chemokines within the vascular endothelium of the lactating breast stroma, including mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Primed B-lymphocytes and antigen-loaded dendritic cells circulating in the lymphatic system home directly to the mammary gland. Within the mammary stroma, B-lymphocytes differentiate into plasma cells that synthesize polymeric IgA targeted against maternal intestinal antigens. This IgA undergoes transcytosis across mammary epithelial cells via the polymeric immunoglobulin receptor (pIgR), entering breast milk as functional secretory IgA (sIgA).

Through the enteromammary pathway, maternal consumption of A07F biotherapeutics leads to a physiological enhancement of milk bioactivity rather than xenobiotic exposure. Breastfed infants are exposed to elevated titers of protective, antigen-specific sIgA immunoglobulins, anti-inflammatory cytokines (such as TGF-$\beta$ and IL-10), and trace quantities of maternal gut-derived commensal strains. This maternal-infant immunological crosstalk supports early neonatal intestinal microbial colonization, promotes immunological tolerance, and reduces the risk of pediatric allergic and infectious diseases.

Randomized clinical trials measuring probiotic presence in human milk after maternal oral administration of Lactobacillus rhamnosus GG or Lactobacillus reuteri demonstrate that maternal supplementation safely modulates the breast milk microbial profile without causing infant distress or bacteremia. The infant exposure resulting from maternal A07F intake is therefore considered physiological, non-toxic, and beneficial to the developing infant gastrointestinal immune system.

Lactological Safety Assessment and Clinical Recommendations

Primary international databases and scientific bodies evaluating drug safety during lactation classify all subclasses of ATC A07F as safe and compatible with breastfeeding.

The specialized reference platform e-lactancia (managed by APILAM) assigns all A07F subclasses its highest safety rating: "Compatible / Very Low Risk" (Producto seguro y/o la lactancia materna es la mejor opción). This rating reflects the total absence of maternal systemic absorption, which precludes drug transfer into human milk. Similarly, the LactMed database maintained by the United States National Library of Medicine categorizes A07F microorganisms as safe during lactation, noting that maternal probiotic intake poses no toxicological hazard to the nursing infant.

Clinical management of lactating women presenting with gastrointestinal disorders can safely incorporate A07F biotherapeutic agents alongside oral rehydration therapy.

For acute infectious gastroenteritis in a lactating mother, oral administration of subclass A07FA01 (Lactobacillus spp.) or subclass A07FA02 (S. boulardii) accelerates clinical recovery and decreases diarrheal duration without requiring suspension of breastfeeding. Maternal fluid intake must be increased to maintain adequate hydration and prevent secondary reductions in milk synthesis.

When treating a lactating mother with systemic antibacterial agents for extra-intestinal infections, co-administration of subclass A07FA02 (S. boulardii) at a dose of 250 mg to 500 mg twice daily effectively reduces the incidence of antibiotic-associated diarrhea (AAD). Because S. boulardii is a fungal organism, it maintains therapeutic activity during co-administration with antibacterial drugs. If subclass A07FA01 or A07FA51 bacterial combinations are selected for AAD prophylaxis, doses should be timed at least 2 hours apart from oral antibacterial administration to prevent premature inactivation of the probiotic bacterial strains.

Specific clinical precautions must be observed in distinct maternal high-risk populations:

• Lactating women with severe absolute neutropenia or advanced immunocompromise should avoid live microbial therapies, particularly S. boulardii, due to the risk of opportunistic translocation and bacteremia or fungemia.
• If a lactating patient requires a central venous catheter (CVC) or peripherally inserted central catheter (PICC), oral S. boulardii capsules or sachet formulations should not be handled near the intravenous access site to prevent aerosol-mediated catheter contamination.
• Lactating patients presenting with severe intestinal mucosal breakdown, such as fulminant colitis or extensive mucosal necrosis, should be managed with non-viable postbiotic preparations or oral rehydration salts rather than live cell formulations.

Under all standard clinical scenarios, maternal administration of ATC class A07F biotherapeutics is fully compatible with continued, uninterrupted lactation. The non-systemic nature of these preparations ensures safety for the breastfed infant while supporting maternal intestinal recovery.